Disrupting cancer through SurVaxM immunotherapy
At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients
News and Events
MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma
MimiVax has received a “study may proceed” letter from the US-FDA to initiate Phase 2b “SURVIVE” study for newly diagnosed glioblastoma.
The Phase 2b “SURVIVE” clinical trial will evaluate SurVaxM in a randomized, blinded, placebo-controlled multi-center study to initially enroll at several U.S. sites. Additional sites in the United States and China to follow.
November 15, 2021
MimiVax to present results of SurVaxM in glioblastoma at ASCO 2019 Meeting
Updated median progression free survival (mPFS) is 15.5 months from diagnosis. Median overall survival (OS) is at 30.5 months from diagnosis. SurVaxM immunotherapy generated encouraging efficacy and immunogenicity in glioblastoma with minimal toxicity.
June 05, 2019
Mimivax looks for game-changer in GBM as SurVaxM shows signal at interim look
In the ongoing study, survival trends strengthened as the data have matured. With the phase II in nGBM so far achieving a survival rate that exceeds the historical standard of care by 40 percent, the study already met its six-month PFS endpoint.
May 21, 2018
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is improving outcomes and quality of life for those suffering from devastating diseases as well as strengthening the biomedical startup ecosystem of Buffalo, New York.
We’re exploring new ways of stimulating the immune system to fight cancer cells leveraging our proprietary survivin-targeting technology.
SurVaxM is presently being studied in glioblastoma (newly diagnosed and recurrent), multiple myeloma and neuroendocrine tumors (NET).
“The Jacobs family has a deep passion for the discovery of new drugs and medical devices that will help ease the suffering and offer improved treatments for patients diagnosed with chronic and terminal diseases.”
"Immunotherapy offers great hope for patients with cancer. Advances in this arena will undoubtedly lead to significant improvements in survival, including for those patients with difficult to treat malignancies. Many experts in the field believe that glioblastoma is potentially susceptible to immunotherapy. Here at MimiVax, we have devoted our lives and careers to uncovering the clues that will help make that belief a reality."
To disrupt cancer with innovative immunotherapies
SurVaxM is currently being evaluated in: a Phase II clinical trial in adults with newly diagnosed glioblastoma; a Phase I clinical trial in combination with REVLIMID® (lenalidomide) for adults with multiple myeloma; and a Phase I clinical trial for metastatic neuroendocrine tumors (NET).
Partner with us
MimiVax is a privately held, clinical-stage biotechnology company that was formed in 2012 from Roswell Park Comprehensive Cancer Center. This was quickly followed by a prestigious award from the American Cancer Society, and support from the Roswell Park Alliance Foundation enabling clinical studies of SurVaxM for glioblastoma. If you are an investor interested in MimiVax, please reach out via the contact form below.
MimiVax is a team of experienced scientists, leading clinicians and industry leaders.
We are committed to pursuing the most efficient and comprehensive path to deliver upon the promise of SurVaxM to improve the lives of those battling cancer.
Help accelerate the pace of SurvaxM clinical trials
The Roswell Park Alliance Foundation is the charitable arm of Roswell Park Comprehensive Cancer Center, where SurVaxM research started. Donations to the Alliance Foundation helped make early phase SurVaxM clinical studies possible and will continue to accelerate the pace and scope of future SurVaxM clinical trials. Please follow this link to make a potentially life changing contribution to this critical effort.